Literature DB >> 27272827

Prognostic Impact of EGFR Driver Mutations on Postoperative Disease Recurrence in Lung Adenocarcinoma.

Tatsuro Okamoto1, Hirokazu Kitahara1, Shinichiro Shimamatsu1, Masakazu Katsura1, Kazuki Takada1, Takatoshi Fujishita1, Yuzo Suzuki1, Yosuke Morodomi1, Tetsuzo Tagawa1, Yoshihiko Maehara2.   

Abstract

AIM: The purpose of this study was to investigate the prognostic significance of epidermal growth factor receptor (EGFR) sensitizing mutations in patients with lung adenocarcinoma who underwent complete surgical resection. PATIENTS AND METHODS: We retrospectively reviewed the clinical records of 164 patients with lung adenocarcinoma who underwent surgery from 2003 to 2010. Seventy-four patients harbored EGFR mutations; two with exon 18 mutations, 27 with exon 19 mutations, and 45 with exon 21 mutations.
RESULTS: There were more female patients and more never-/light smokers among patients with EGFR mutations than among patients without EGFR mutations. Patients with EGFR mutations had a trend for better disease-free survival and overall survival compared to patients without EGFR mutations (p=0.068 and p=0.049, respectively). Patients with exon 21 mutations had significantly better disease-free survival than patients with exon 19 mutations (p=0.027).
CONCLUSION: Adenocarcinomas harboring EGFR exon 21 mutation were less malignant than adenocarcinomas harboring exon 19 mutation. Copyright
© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Non-small cell lung cancer; adenocarcinoma; epidermal growth factor receptor; mutation; prognosis

Mesh:

Substances:

Year:  2016        PMID: 27272827

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  Comment on prognostic value of epidermal growth factor receptor mutation subtypes in surgically resected non-small cell lung cancer.

Authors:  Yujin Kudo; Yoshihisa Shimada; Hisashi Saji; Norihiko Ikeda
Journal:  J Thorac Dis       Date:  2017-05       Impact factor: 2.895

2.  Prognostic impact of pretreatment T790M mutation on outcomes for patients with resected, EGFR-mutated, non-small cell lung cancer.

Authors:  Yoshiya Matsumoto; Tomoya Kawaguchi; Masaru Watanabe; Shun-Ichi Isa; Masahiko Ando; Akihiro Tamiya; Akihito Kubo; Chiyoe Kitagawa; Naoki Yoshimoto; Yasuhiro Koh
Journal:  BMC Cancer       Date:  2022-07-15       Impact factor: 4.638

3.  Tumor Differentiation and EGFR Mutation Associated with Disease-Free Survival in Stage IA Lung Adenocarcinoma Patients with Curative Surgery.

Authors:  Lu Yang; Chong Pang; Fei Xu; Guangjian Yang; Haiyan Xu; Changli Wang; Yan Wang
Journal:  Cancer Manag Res       Date:  2020-12-07       Impact factor: 3.989

4.  Association of Clinicopathologic and Molecular Tumor Features With Recurrence in Resected Early-Stage Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.

Authors:  Stephanie P L Saw; Siqin Zhou; Jianbin Chen; Gillianne Lai; Mei-Kim Ang; Kevin Chua; Ravindran Kanesvaran; Quan Sing Ng; Amit Jain; Wan Ling Tan; Tanujaa Rajasekaran; Darren W T Lim; Aaron Tan; Kam Weng Fong; Angela Takano; Xin Ming Cheng; Kiat Hon Lim; Tina Koh; Boon-Hean Ong; Eng Huat Tan; Chee Keong Toh; Anders J Skanderup; Sze Huey Tan; Daniel S W Tan
Journal:  JAMA Netw Open       Date:  2021-11-01

5.  Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study.

Authors:  Xue-Ning Yang; Hong-Hong Yan; Jun Wang; Xiang-Yang Chu; Zhi-Dong Liu; Yi Shen; Hai-Tao Ma; Xiang-Ning Fu; Jian Hu; Nai-Kang Zhou; Yong-Yu Liu; Xin-Ming Zhou; Jing-Song Li; Kang Yang; Jian Li; Lin Xu; Si-Yu Wang; Qun Wang; Lun-Xu Liu; Shun Xu; Zhong-Yuan Chen; Hong-He Lou; Chang-Li Wang; Ying Cheng; Si-Yang Liu; Xu-Chao Zhang; Wen-Zhao Zhong; Yi-Long Wu
Journal:  JTO Clin Res Rep       Date:  2021-11-25

Review 6.  Updated Prognostic Factors in Localized NSCLC.

Authors:  Simon Garinet; Pascal Wang; Audrey Mansuet-Lupo; Ludovic Fournel; Marie Wislez; Hélène Blons
Journal:  Cancers (Basel)       Date:  2022-03-09       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.